|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肿瘤患者PICC致静脉血栓的原因分析及护理显示文摘目的分析肿瘤患者PICC致静脉血栓的原因,总结有效的预防护理措施。方法患者于化疗当日行PICC置管,并给予观察与护理。结果416例患者中14例发生静脉血栓,发生率3.4%;经溶栓、抗凝治疗后,13例2~10d症状逐渐缓解,1例溶栓治疗中发生栓子脱落引起脑栓塞。结论肿瘤患者PICC致静脉血栓是不容忽视的并发症;应给予有效的预防护理措施,预防静脉血栓的发生;应在抗凝和溶栓过程中密切观察出血倾向及栓子脱落导致其他部位栓塞的征象。 | 刁永书 李虹 许辉琼 汪秀云 易琼 袁灵 | 2005 | 中国实用护理杂志(下旬版)2005，21，6： | 135 |
| 2 | Growth inhibition and apoptosis induction Sulindac on Human gastric cancer cells显示文摘AIM: To evaluate the effects of sulindac in inducing growth inhibition and apoptosis of human gastric cancer cells in comparison with human hepatocellular carcinoma (HCC)cells.METHODS: The human gastric cancer cell lines MKN45 and MKN28 and human hepatocellular carcinoma cell lines HepG2and SMMC7721 were used for the study. Anti-proliferative effect was measured by MTT assay, and apoptosis was determined by Hoechst-33258 staining, electronography and DNA fragmentation. The protein of cyclooxygenase-2 (COX(2) and Bcl-2 were detected by Westem dot blotting.RESULTS: Sulindac could initiate growth inhibition and apoptosis of MKN45, MKN28, HepG2 and SMMC7721 cells in a dose-and time-dependent manner. Growth inhibitory activity and apoptosis were more sensitive in HepG2 cells than in SMMC7721 cells, MKN45 and MKN28 cells. After 24hours incubation with sulindac at 2mmol. L-1 and 4mmol.L-1, the level of COX-2 and Bcl-2 protein were lowered in MKN45, SMMC7721 and HepG2 cells but not in MKN28 cells.CONCLUSION: Sulindac could inhibit the growth of gastric cancer cells and HCC cells effectively in vitro by apoptosis induction, which was associated with regression of COX-2and Bcl-2 expression. The growth inhibition and apoptosis of HCC cells were greater then that of human gastric cancer cells. The different effects of apoptosis in gastric cancer cells may be related to the differentiation of the cells. | Yun-Lin Wu~1 Bo Sun~1 Xue-Jun Zhang~2 Sheng-Nian Wang~2 Heng-Yi He~2 Min-Min Qiao~1 Jie Zhong~1 Jia-Yu Xu~1 1 Department of Gastroenterology,Ruijin Hospital,Shanghai Second Medical University,Shanghai 200025,China2 Institude of Biochemistry and Cell Biology,Shanghai Institues for Biological Sciences,Chinese Academy of Sciences.Shanghai 200025,China | 2001 | World Journal of Gastroenterology2001，7，6： | 64 |
| 3 | 应用射频消融法对肝肿瘤患者进行规范化治疗显示文摘目的探讨射频消融(RFA)规范化治疗及综合措施对提高肝肿瘤疗效的应用价值。方法302例计476个肝脏恶性肿瘤行RFA治疗,应用规范化治疗方案及附加治疗方法,总结疗效。原发性肝癌(HCC)181例,282个癌灶,肿瘤大小平均4.2cm。肝转移癌(MLC)121例,194个癌灶,肿瘤大小平均3.9cm。根据肿瘤大小、形态及邻近膈肌、胆囊、胃肠等不同位置,采用相应的规范化方案及个体化方案相结合治疗;重视相邻重要结构区域的消融布针方法及操作技巧;应用辅助定位、局部注水、加强肿瘤血管消融等附加方法综合治疗。结果综合应用以上方法,RFA后1个月增强CT或超声造影显示肿瘤灭活率HCC为95.7%(270/282),MLC为94.8%(184/194);邻近肠管肿瘤为91.1%(51/56),邻近膈肌肿瘤为88.5%(69/78),邻近胆囊肿瘤为94.3%(49/52)。随访3~57个月,局部复发率HCC为10.3%(29/282),MLC为14.4%(28/194)。患者1年、2年、3年的生存率HCC为87.6%、67.4%、58.6%;其中50例Ⅰ~Ⅱ期肝癌的生存率分别为90.7%、85.9%、73.7%。MLC为87.4%、48.2%、25.3%。并发症占2.2%(13/583);分别为出血5例,采用局部消融、全身用药等处理措施;肠穿孔1例,对邻近肠管肿瘤采用治疗后延长禁食时间等措施进行预防。余7例为邻近脏器结构轻度损伤,无与射频治疗相关死亡。结论采用规范化RFA治疗方案及适宜的个体化治疗方案,重视附加方法的应用,有助于提高肝肿瘤灭活率;掌握主要并发症的类型及对应预防措施,是提高疗效及推广RFA治疗的重要环节。 | 陈敏华 杨薇 严昆 高文 戴莹 王艳滨 霍苓 张晖 黄信孚 | 2005 | 中华医学杂志2005，85，25： | 70 |
| 4 | 肝细胞癌合并门静脉癌栓的手术切除及疗效观察显示文摘目的探索肝细胞癌合并门静脉癌栓(PVTT)手术切除的疗效及其影响预后因素。方法总结近10年111例肝细胞癌合并门静脉主干或第一分支癌栓的患者,均行肝癌联同门静脉左或右支癌栓切除或经左、右支断端取栓或切开主干取栓,其中22例患者切除肿瘤及癌栓后行肝动脉和(或)门静脉插管。32例患者术后经肝动脉化疗栓塞和(或)经门静脉导管化疗。另14例PVTT患者仅行保守治疗(非手术组),20例PVTT患者行探查或肝动脉结扎插管和(或)门静脉插管化疗(未切除组)。结果手术切除组术后1、2、3、4、5年生存率分别为617%、362%、323%、244%、224%,而14例非手术患者均于3个月内死亡,20例未切除患者术后1、2年生存率分别为60%及0。结论肝细胞癌合并PVTT行手术切除可提高术后综合疗效,改善患者生活质量,延长生存期。 | 樊嘉 吴志全 汤钊猷 余业勤 周俭 邱双健 张博恒 | 1999 | 中华外科杂志1999，37，1： | 63 |
| 5 | Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level显示文摘AIM: To investigate the expression level of plasma vascularendothelial growth factor (P-VEGF) in patients withhepatocellular carcinoma (HCC) and its relationship withthe clinicopathologic characteristics, and to examine thechanges of P-VEGF in the course of transcatheter arterialchemoembolization (TACE).METHODS: Peripheral blood samples were taken from 45HCC patients before and 1, 3, 7 d, and 1 mo after TACE.Plasma VEGF level was measured with the quantitativesandwich enzyme-linked immunosorbent assay (ELISA).Twenty patients with benign liver lesions and 17 healthycontrol subjects were also included in this study.RESULTS: Plasma VEGF levels in HCC patients weresignificantly elevated as compared to those in patients withbenign liver lesions (P = 0.006) and in the normal controls(P = 0.003). Significant differences were observed whenP-VEGF was categorized by tumor size (P = 0.006), portalvein thrombosis (P= 0.011), distant metastasis (P= 0.017),arterial-portal vein shunting (P = 0.026), and InternationalUnion Against Cancer (UICC) TNM stage (P = 0.044). Therewas no correlation between plasma level of VEGF and thelevel of alpha fetoprotein (^-FP) (r = 0.068, P = 0.658) andweakly correlated with the number of platelets (r = 0.312,P = 0.038). P-VEGF levels increased significantly andreached the peak value on the first day after TACE, and thendecreased gradually. The change rate of P-VEGF concentration(one month post-TACE/pre-TACExl00%) was correlatedwith the retention rate of lipiodol oil (rs = 0.494, P= 0.001)and the tumor volume change (r s = 0.340, P = 0.034).The patients who achieved a partial or complete responseto TACE therapy showed significantly less pre-treatmentP-VEGF than those nonresponders (P = 0.025). A high pre-therapeutic P-VEGF level was associated with poor responseto treatment (P = 0.018).CONCLUSION: A high pre-treatment P-VEGF level is auseful marker for tumor nroeression, esBeciallv for vascularinvasion. TACE increases the level of P-VEGF onlytemporarily which may be associated with tumor ischemia.P-VEGF may be useful in predicting treatment response,monitoring disease course after TACE and judging the effectof different TACE regimens. | XinLi Gan-ShengFeng Chuan-ShengZheng Chen-KaiZhuo XiLiu | 2004 | World Journal of Gastroenterology2004，10，19： | 53 |
| 6 | Expression of hypoxia-inducible factor la and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival显示文摘AIM: To study the expression of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF)in hepatocellular carcinoma (HCC) and the impact on neovascularization and survival.METHODS: Expressions of HIF-1α, VEGF and microvessel density (MVD) are studied through immunohistochemistry in 36 cases of HCC and the corresponding paraneoplastic tissue and 6 cases of normal liver tissue. The relationship of the expressions of HIF-1α and VEGF with the clinicopathological data and survival are analyzed.RESULTS: The positive rate of VEGF in HCC was 32/36,which is significantly higher than that in paraneoplastic tissue and normal liver tissue (P<0.05). The expression of HIF-1α in HCC tissue is 24/36, also higher than that in paraneoplastic tissue and normal liver tissue (P<0.05). The expression of VEGF and HIF-1α in HCC with microscopic venous invasion is significantly higher than that in HCC without microscopic venous invasion (P<0.05). Spearman correlation analysis does not only show the expression of HIF-1α as correlated with the expression of VEGF (rs = 0.459, P<0.01), but it also shows the expression of HIF-1α and VEGF as correlated with MVD (rs = 0.412 and 0.336, respectively, P<0.05). The differences of the survival rates among VEGF positive group and VEGF negative group are significant (P<0.05), whereas the differences of the survival rates among the HIF-1α negative group and positive group are not significant (P>0.05).CONCLUSION: HIF-1α plays important roles in neovascularization in HCC possibly through regulation of VEGF transcription. | Geng-WenHuang Lian-YueYang Wei-QunLu | 2005 | World Journal of Gastroenterology2005，11，11： | 51 |
| 7 | 重质油裂解制烯烃的HCC工艺显示文摘H C C 工艺( Heavy - oil Contact Cracking Process) 是针对乙烯生产原料重质化而开发研究的。主要是采用类似于催化裂化的流态化“反应- 再生”工艺技术,在性能良好的催化剂上,实现重油直接裂解制乙烯,并兼产丙烯、丁烯和轻质芳烃,有效地拓宽了乙烯生产原料的选择范围。在典型的工艺条件下,不同的重质原料油( B M C I 值为20 ~50) 在中型提升管装置上,其乙烯质量产率可达19 % ~27 % ,其中,石蜡基常压渣油在优化的工艺条件下, C2 ~ C4 总烯烃质量产率超过50 % 。 | 沙颖逊 崔中强 王明党 王国良 张洁 | 1999 | 石油化工1999，28，9： | 53 |
| 8 | Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma显示文摘AIM: To evaluate the therapeutic efficacy of threedimensional conformal radiotherapy (3D-CRT) combined with transcatheter arterial chernoembolization (TACE) on the patients with hepatocellular carcinoma (HCC).METHODS: Between 1998 and 2001, 94 patients with HCC received 3D-CRT combined with TACE. A total 63 patients had a Okuda stage Ⅰ lesion and 31 patients had stage Ⅱ. The median tumor size was 10.7 cm (range 3.0-18 cm), and liver drrhosis was present in all the patients. There were 43 cases of class A and 51 dass B. TACE was performed using lipiodol,5-fluorouracil, cisplatin, doxorubicin hydrochloride and mitomycin, followed by gelatin sponge cubes. Fifty-nine patients received TACE only one time, while the others 2 to 3 times. 3D-CRT was started 3-4 wk after TACE. All patients were irradiated with a stereotactic body frame and received 4-8 Gy single high-dose radiation for 8-12 times at the isocenter during a period of 17-26 d (median 22 d).RESULTS: The median follow-up was 37 mo (range 10-48 mo) after diagnosis. The response rate was 90.5%. The overallsurvival rate at 1-, 2-, and 3- year was 93.6%, 53.8% and 26.0% respectively, with the median survival of 25 too. On univariate analysis, age (P=-0.026), Child-Pugh classification for cirrhosis of liver (P=0.010), Okuda stage (P=-0.026),tumor size (P=0.000), tumor type (P=0.029), albuminemia (P=0.035), and radiation dose (P=0.000) proved to be significant factors for survival. On multivariate analysis,age (P=-0.024), radiation dose(P=-0.001), and tumor size (P=0.000) were the significant factors.CONCLUSION: 3D-CRT combined with TACE is an effective and feasible approach for HCC. Age, radiation dose and tumor size were found to be significant prognostic factors for survival of patients with HCC treated by 3D-CRT combined with TACE. Further study for HCC is needed to improve the treatment efficacy. | De-HuaWU LiLiu Long-HuaChen | 2004 | World Journal of Gastroenterology2004，10，15： | 45 |
| 9 | Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma显示文摘AIM: To investigate the prognostic role of isoform 165 vascular endothelial growth factor messenger RNA (VEGF165 mRNA)in noncancerous liver tissues from patients with primary hepatocellular carcinoma (HCC).METHODS: Using a reverse-transcription polymerase chain reaction (RT-PCR)-based assay, VEGF mRNA was determined prospectively in noncancerous liver tissues from 60 consecutive patients with HCC undergoing curative resection. We categorized the patients with VEGF165 mRNA over 0.500 in noncancerous liver tissues as group A, and those below 0.500 as group B.RESULTS: Among the isoforms of VEGF mRNA by multivariate analysis, a higher level of VEGF165 mRNA in noncancerous liver tissue correlated significantly with a higher risk of HCC recurrence (P = 0.039) and recurrence-related mortality (P= 0.048), but VEGF121 did not. The other significant predictors of recurrence consisted of vascular permeation (P = 0.022),daughter nodules (P = 0.033), cellular dedifferentiation (P = 0.033), an absent or incomplete capsule (P = 0.037).A significant variable of recurrence-related mortality was Vascular permeation (P= 0.012). As to the clinical manifestations of 16 patients who developed recurrence,the recurrent tumor number over 2, recurrent extent over two-liver segments, and the median survival after recurrence,all significantly correlated with group A patients (P = 0.043,0.043, and 0.048, respectively). However, the presence of extrahepatic metastasis was not (P>0.05). The difference in recurrence after treatment between the two groups had no statistical significance (P>0.05).CONCLUSION: The higher expression of isoform VEGF165mRNA in noncancerous liver remnant of patients with HCC may be a significant biological indicator of the invasiveness of postoperative recurrence. | I-ShyanSheen Kuo-ShyangJeng Shou-ChuanShih Chih-RoaKao Wen-HsingChang Horng-YuanWang Po-ChuanWang Tsang-EnWang Li-RungShyung Chih-ZenChen | 2005 | World Journal of Gastroenterology2005，11，2： | 41 |
| 10 | 肝动脉栓塞化疗后射频消融联合酒精消融对原发性肝癌的疗效评价显示文摘目的 探讨肝动脉栓塞化疗(TACE)后,CT导向下射频消融(RFA)联合无水乙醇消融(PEI)对原发性肝癌(HCC)的治疗效果。方法 经病理、AFP或典型影像学诊断证实的HCC 1 5 0例,每例肝内的病灶数目<3个,病灶大小3.1~7.9cm ,平均直径5 .5cm。全部患者按就诊单双日分为对照组和联合组。对照组74例,TACE后2周行单纯RFA ;联合组76例,TACE后2周行射频消融,间隔2 0~30d后再行PEI。结果 对照组的完全坏死率为75 .8%,联合组为89.5 %,两组间差异有统计学意义(P <0 .0 5 )。结论 HCC患者经TACE后,行CT导向下RFA联合PEI的疗效明显优于单纯RFA。 | 张福君 吴沛宏 赵明 顾仰葵 张亮 谭志斌 | 2005 | 中华肿瘤杂志2005，27，4： | 48 |
| 11 | Diagnosis of hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide, particularly in parts of the developing world, and is increasing in incidence. This article reviews the current modalities employed for the diagnosis of HCC, including serum markers, radiological techniques and histological evaluation, and summarises international guidelines for the diagnostic approach to HCC. | Asmaa I Gomaa Shahid A Khan Edward LS Leen Imam Waked Simon D Taylor-Robinson | 2009 | World Journal of Gastroenterology2009，15，11： | 44 |
| 12 | Current management strategy of hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) still remains a considerable challenge for surgeons.Surgery,including liver transplantation,is the most important therapeutic approach for patients with this disease.HCC is frequently diagnosed at advanced stages and has a poor prognosis with a high mortality rate even when surgical resection has been considered potentially curative.This brief report summarizes the current status of the management of this malignancy and includes a short description of new pharmacological approaches in HCC treatment. | Bernardino Rampone Beniamino Schiavone Antonio Martino Carmine Viviano Giuseppe Confuorto | 2009 | World Journal of Gastroenterology2009，15，26： | 50 |
| 13 | Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients显示文摘AIM: To identify prognostic factors of patients with hepatocellular carcinoma (HCC), who were treated by orthotopic liver transplantation (OLT). METHODS: From January 2000 to October 2006, 165 patients with HCC underwent OLT. Various clinicopathological risk factors for actuarial and recurrence-free survival were identified using the Kaplan-Meier method with the log-rank test. The Cox proportional hazards model was used to identify independently predictive factors for actuarial and recurrence-free survival, which were used to propose new selection criteria. We compared the outcome of the subgroup patients meeting different criteria. Survival analysis was performed using the Kaplan-Meier method with the log-rank test. RESULTS: The median follow-up was 13.0 mo (2.8-69.5 mo). Overall, 1-, 2-, 3-and 5-year actuarial survival was 73.3%, 45.6%, 35.4% and 32.1%, respectively. One-, 2-, 3-and 5-year overall recurrencefree survival was 67.0%, 44.3%, 34.5% and 34.5%, respectively. In univariate analysis, number of tumors, total tumor size, lobar distribution, differentiation, macrovascular invasion, microvascular invasion, capsulationof the tumor, and lymph node metastasis were found to be associated significantly with actuarial and tumor-free survival. By means of using the multivariate Cox proportional hazards model, total tumor size and macrovas-cular invasion were found to be independent predictors of actuarial and tumor-free survival. When the selection criteria were expanded into the proposed criteria, there was no significant difference in 1-, 2-, 3-and 5-year actuarial and tumor-free survival of the 49 patients who met the proposed criteria (97.6%, 82.8%, 82.8% and 82.8%, and 90.7%, 82.8%, 68.8% and 68.8%, respectively) compared with that of patients who met the Milan or University of California, San Francisco (UCSF) criteria. CONCLUSION: Macrovascular invasion and total tumor diameter are the strongest prognostic factors. The proposed criteria do not adversely affect the outcome of liver transplantation for HCC, compared with the Milan or UCSF criteria. | Jin Li Lu-Nan Yan Jan Yang Zhe-Yu Chen Bo Li Yong Zeng Tian-Fu Wen Ji-Chun Zhao Wen-Tao Wang Jia-Yin Yang Ming-Qing Xu Yu-Kui Ma | 2009 | World Journal of Gastroenterology2009，15，33： | 37 |
| 14 | 42,573 cases of hepatectomy in China: a multicenter retrospective investigation显示文摘Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma(HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients,81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein(AFP) level, and other 35% had an AFP level lower than 400 ng mL^(-1). In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was(191.7±105.6) min,the blood loss was(546.0±562.8) m L, and blood transfusion was(543.0±1,035.2) m L. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules,tumor thrombosis and high AFP level were risk factors that affect postoperative survival. | Binhao Zhang Bixiang Zhang Zhiwei Zhang Zhiyong Huang Yifa Chen Minshan Chen Ping Bie Baogang Peng Liqun Wu Zhiming Wang Bo Li Jia Fan Lunxiu Qin Ping Chen Jingfeng Liu Zhe Tang Jun Niu Xinmin Yin Deyu Li Songqing He Bin Jiang Yilei Mao Weiping Zhou Xiaoping Chen | 2018 | Science China(Life Sciences)2018，61，6： | 39 |
| 15 | Growth inhibition and apoptosis induction of tanshinone Ⅱ-A on human hepatocellular carcinoma cells显示文摘AIM: To evaluate the effects of tanshinone II-A on inducing growth inhibition and apoptosis of human hepatocellular carcinoma (HCC) cells,METHODS: The human hepatocellular carcinoma cell line SMMC-7721 was used for the study. The cells were treated with tanshinone II-A at different doses and different times.Cell growth and proliferation were measured by MTT assay,cell count and colony-forming assay. Apoptosis induction was detected by microscopy, DNA ladder electrophoresis and flow cytometry.RESULTS: In MTT assay, the inhibitory effect became gradually stronger with the passage of time, 24, 48, 72and 96 h after treatment with tanshinone II-A, and the most significant effect was observed at 72 h. On the other hand, the increase of doses (0.125, 0.25, 0.5, 1.0 mg/L tanshinone II-A) resulted in enhanced inhibitory effect.The growth and proliferation of SMMC-7721 cells were obviously suppressed in a dose- and time-dependent manner. The results of cell count were similar to that of MTT assay. In colony-forming assay, the colony-forming rates were obviously inhibited by tanshinone II-A. In tanshinone II-A group, the morphology of cellular growth inhibition and characteristics of apoptosis such as chromatin condensation, crescent formation, margination and apoptotic body were observed under light and transmission electron microscopes. DNA ladder of cells was presented in electrophoresis. The apoptosis index (AI) was 16.9% (the control group was 4.6%) in flow cytometry. The cells were arrested in G0/G1 phase, and the expressions of apoptosis-related genes bd-2 and c-myc were down-regulated and fas, bax, p53 up-regulated.CONCLUSION: Tanshinone II-A could inhibit the growth and proliferation of HCC cell effectively in vitro by apoptosis induction,which was associated with up-regulation of fas, p53, bax,expression and down-regulation of bcl-2 and c-myc. | Shu-LanYuan Yu-QuanWei Xiu-JieWang FeiXiao Sheng-FuLi JieZhang | 2004 | World Journal of Gastroenterology2004，10，14： | 31 |
| 16 | Hepatocellular carcinoma treated with interventional procedures:CT and MRI follow-up显示文摘In the past decade, a variety of interventional procedures have been employed for local control of hepatocellular carcinoma (HCC). These include transcather arterial chemoembolization (TACE) and several tumour ablation techniques, such as percutaneous ethanol injection (PEI),radio-frequency ablation (RFA), or percutaneous microwave coagulation therapy (PMC), laser-induced interstitial thermotherapy (LIFr), etc. For a definite assessment of the therapeutic efficacy of interventional procedures,histological examination using percutaneous needle biopsy may be the most definite assessment of the therapeutic efficacy of interventional therapy, however, it is invasive and the specimen retrieved does not always represent the entire lesion owing to sampling errors. Therefore, computed tomography (CT) and magnetic resonance imaging (MRI) play a crucial role in follow-up of HCC treated by interventional procedures, by which the local treatment efficacy, recurrent disease and some of therapy-induced complications are evaluated. Contrast enhanced axial imaging (CT or MR imaging) may be the most sensitive test for assessing the therapeutic efficacy. The goal of the review was to describe the value of CT and MRI in the evaluation of interventional treatments. | Yong-SongGuan LongSun Xiang-PingZhou XiaoLi Xiao-HuaZheng | 2004 | World Journal of Gastroenterology2004，10，24： | 31 |
| 17 | 肝细胞癌TACE术后严重并发症分析显示文摘目的 评价经导管肝动脉化疗栓塞术 (TACE)治疗肝细胞癌 (HCC)的严重并发症。方法 回顾分析 5 5 6例原发性肝癌患者 10 0 0次TACE术后出现的近期严重并发症。结果 本组TACE包括上消化道大出血 3次 ( 0 .3 % ) ,肝功能衰竭 2 6例 ( 2 .6% ) ,碘油肺栓塞 5例 ( 0 .5 % ) ,碘油脑栓塞 2例 ( 0 .2 % )及肝脓肿 2例 ( 0 .2 % )。结论 肝癌TACE术后严重并发症直接影响到病人的预后 ,应重视并预防其发生 。 | 崔艳峰 祖茂衡 徐浩 顾玉明 李国均 张庆桥 魏宁 | 2005 | 中国介入影像与治疗学2005，2，1： | 34 |
| 18 | Comparison of laparoscopic vs open liver lobectomy(segmentectomy) for hepatocellular carcinoma显示文摘AIM:To investigate the effects of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma(HCC) .METHODS:From 2006 to January 2011,laparoscopic hepatectomies were performed on 30 cases of HCC at Northern Jiangsu People's Hospital. During this sametime period,30 patients elected to undergo conventional open hepatectomy over laparoscopic hepatectomy at the time of informed consent. The degree of invasiveness and outcomes of laparoscopic hepatectomy compared to open hepatectomy for HCC were evaluated.RESULTS:Both groups presented with similar bloodloss amounts,operating times and complications. Patients in the laparoscopic hepatectomy group started walking and eating significantly earlier than those inthe open hepatectomy group,and these more rapid recoveries allowed for shorter hospitalizations. There were no significant differences between procedures insurvival rate.CONCLUSION:Laparoscopic hepatectomy is beneficial for patient quality of life if the indications are appropriately based on preoperative liver function and the location and size of the HCC. | Ben-Shun Hu Ke Chen Hua-Min Tan Xiang-Ming Ding Jing-Wang Tan | 2011 | World Journal of Gastroenterology2011，17，42： | 32 |
| 19 | Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma显示文摘Sorafenib is the first-line medication for advanced hepatocellular carcinoma(HCC),but it can only extend limited survival.It is imperative to find a combination strategy to increase sorafenib efficacy.Artesunate is such a preferred candidate,because artesunate is clinically well-tolerated and more importantly both drugs can induce ferroptosis through different mechanisms.In this study we investigated the combined effect of sorafenib and artesunate in inducing ferroptosis of HCC and elucidated the involved molecular mechanisms.We showed that artesunate greatly enhanced the anticancer effects of low dose of sorafenib against Huh7,SNU-449,and SNU-182 HCC cell lines in vitro and against Huh7 cell xenograft model in Balb/c nude mice.The combination index method confirmed that the combined effect of sorafenib and artesunate was synergistic.Compared with the treatment with artesunate or sorafenib alone,combined treatment induced significantly exacerbated lipid peroxidation and ferroptosis,which was blocked by N-acetyl cysteine and ferroptosis inhibitors liproxstatin-1 and deferoxamine mesylate,but not by inhibitors of other types of cell death(z-VAD,necrostatin-1 and belnacasan).In Huh7 cells,we demonstrated that the combined treatment induced oxidative stress and lysosome-mediated ferritinophagy,two essential aspects of ferroptosis.Sorafenib at low dose mainly caused oxidative stress through mitochondrial impairments and SLC7A11-invovled glutathione depletion.Artesunate-induced lysosome activation synergized with sorafenib-mediated pro-oxidative effects by promoting sequential reactions including lysosomal cathepsin B/L activation,ferritin degradation,lipid peroxidation,and consequent ferroptosis.Taken together,artesunate could be repurposed to sensitize sorafenib in HCC treatment.The combined treatment can be easily translated into clinical applications. | Zhong-jie Li Hui-qi Dai Xiao-wei Huang Ji Feng Jing-huan Deng Zi-xuan Wang Xiao-mei Yang Yu-jia Liu Yong Wu Pan-hong Chen Huan Shi Ji-gang Wang Jing Zhou Guo-dong Lu | 2021 | Acta Pharmacologica Sinica2021，42，2： | 31 |
| 20 | 肝细胞癌CT灌注参数与微血管密度的相关性研究显示文摘目的探讨肝细胞癌(HCC)的CT灌注参数与微血管密度(MVD)之间的相关性。方法以18例行CT灌注扫描检查并经病理及免疫组织化学染色证实的患者为研究对象。CT灌注扫描计算的血供参数包括肝动脉灌流量(HAP)、门静脉灌流量(PVP)、肝总灌流量(TLP)、肝动脉灌流指数(HAI)、门静脉灌流指数(PVI)。病理组织切片经HE及CD34染色,确定癌细胞分化程度及测定组织MVD。分析CT灌注参数与肿瘤恶性程度及MVD之间的相关性。结果18例中,高分化HCC5例,中分化HCC7例,低分化HCC6例。MVD分别为高分化组736个/mm2,中分化组1667个/mm2,低分化组2382个/mm2。各组灌注参数HAP、PVP、TLP、HAI、PVI分别依次为高分化组0478ml·min-1·ml-1、0441ml·min-1·ml-1、0918ml·min-1·ml-1、052、048;中分化组1216ml·min-1·ml-1、0587ml·min-1·ml-1、1803ml·min-1·ml-1、067、033;低分化组1103ml·min-1·ml-1、0473ml·min-1·ml-1、1576ml·min-1·ml-1、071、029。结果表明,高分化HCC的MVD、PVP、TLP、HAI最低,PVI最高(P值均<001);中分化HCC的PVP、TLP最高(P<001);低分化HCC的MVD、HAI最高,PVI最低(P<005)。结论CT灌流指数是反映肿瘤恶性程度及肿瘤血管生成的较好指标。 | 文利 丁仕义 牟伟 周代全 陈洁 张哉根 | 2005 | 中华放射学杂志2005，39，3： | 30 |
您所在的机构暂未开通此部分的功能，请联系管理员